Emily Hsu

4.0k total citations · 2 hit papers
29 papers, 705 citations indexed

About

Emily Hsu is a scholar working on Genetics, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Emily Hsu has authored 29 papers receiving a total of 705 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 9 papers in Oncology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Emily Hsu's work include Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (7 papers) and Advanced Breast Cancer Therapies (4 papers). Emily Hsu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (7 papers) and Advanced Breast Cancer Therapies (4 papers). Emily Hsu collaborates with scholars based in United States, Spain and Italy. Emily Hsu's co-authors include Alessandra Tedeschi, Carol Moreno, Cathy Zhou, Fatih Demırkan, Devinder Gill, Martin Šimkovič, Jan Novák, Bertrand Anz, Владимир Стругов and John G. Gribben and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Emily Hsu

26 papers receiving 694 citations

Hit Papers

Ibrutinib plus obinutuzumab versus chlorambucil plus obin... 2018 2026 2020 2023 2018 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
    2018 380 citations Carol Moreno, Richard Greil et al. The Lancet Oncology profile →
  2. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 
    2022 146 citations Paul M. Barr, Carolyn Owen et al. Blood Advances profile →

Peers

Emily Hsu
Sandra Dai United States
Luciano Levato Italy
Andrzej Pluta Poland
Elizabeth Bilotti United States
M Levade France
Amalia Vassou Greece
Roberto Freilone Italy
Carla Pieresca Italy
Sotirios Sachanas Greece
Daniele Bertoloni Italy
Sandra Dai United States
Emily Hsu
Citations per year, relative to Emily Hsu Emily Hsu (= 1×) peers Sandra Dai

Countries citing papers authored by Emily Hsu

Since Specialization
Citations

This map shows the geographic impact of Emily Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Hsu more than expected).

Fields of papers citing papers by Emily Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Hsu. The network helps show where Emily Hsu may publish in the future.

Co-authorship network of co-authors of Emily Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Hsu. A scholar is included among the top collaborators of Emily Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Hsu. Emily Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thomas, Scott, Nela Pawłowska, Diana Bauer, et al.. (2025). Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant. Scientific Reports. 15(1). 3028–3028.
2.
Sarkar, Indra Neil, et al.. (2024). An Intersectional Approach to Cervical Cancer Screening Disparities by Race/Ethnicity and Immigrant Status. Journal of Women s Health. 34(2). 261–270. 1 indexed citations
3.
4.
Adeyelu, Tolulope, Andrew Elliott, Phillip L. Walker, et al.. (2024). Genomic and transcriptomic landscape of HER2-low breast cancer. Breast Cancer Research and Treatment. 209(2). 323–330. 4 indexed citations
5.
Hsu, Emily, et al.. (2024). Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer. Current Treatment Options in Oncology. 25(10). 1323–1334. 1 indexed citations
6.
Woyach, Jennifer A., Paul M. Barr, Thomas J. Kipps, et al.. (2023). Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study. Cancers. 15(2). 507–507. 10 indexed citations
7.
Graff, Stephanie L., Andrew Elliott, Estelamari Rodríguez, et al.. (2023). 215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer. ESMO Open. 8(1). 101404–101404. 3 indexed citations
8.
Bustos, Matías A., Estelamari Rodríguez, Sarah Sammons, et al.. (2023). Abstract HER2-12: HER2-12 Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer. Cancer Research. 83(5_Supplement). HER2–12. 2 indexed citations
9.
Sarkar, Indra Neil, et al.. (2023). An intersectional approach to cervical cancer screening disparities by race/ethnicity and immigrant status.. Journal of Clinical Oncology. 41(16_suppl). 6536–6536. 1 indexed citations
10.
Barr, Paul M., Carolyn Owen, Tadeusz Robak, et al.. (2022). Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia . Blood Advances. 6(11). 3440–3450. 146 indexed citations breakdown →
11.
12.
Hsu, Emily, et al.. (2022). Defining the Current Landscape, Attitudes, and Perceived Barriers of Virtual Medicine in Underserved Populations. JCO Oncology Practice. 18(12). e1987–e1995. 2 indexed citations
13.
Hsu, Emily, et al.. (2022). Collaborating Together, Coordinating Better? Examining Emotional and Physiological Dynamics in Teams. Academy of Management Proceedings. 2022(1). 1 indexed citations
14.
Hsu, Emily, et al.. (2021). Social determinants of health and the Barrio Advantage among Hispanics during the COVID-19 pandemic.. Journal of Clinical Oncology. 39(28_suppl). 133–133. 1 indexed citations
15.
Moreno, Carol, Richard Greil, Fatih Demırkan, et al.. (2018). Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(1). 43–56. 380 indexed citations breakdown →
16.
Hsu, Emily, et al.. (2018). A Case of Granulocytic Sarcoma or Extramedullary Acute Myelomonocytic Leukemia of the Gallbladder. American Journal of Case Reports. 19. 1262–1266. 6 indexed citations
17.
Hsu, Andrew, et al.. (2017). Emphysematous Gastritis: A Rare and Lethal Cause of Severe Abdominal Pain. The American Journal of Gastroenterology. 112. S1446–S1447.
18.
Homel, Peter, et al.. (2015). Young Patients With Diabetes Have Decreased Cerebrovascular Reactivity Under Hypercapneic Conditions. Pediatric Neurology. 53(6). 498–502. 4 indexed citations
19.
Stämmler, Frank, et al.. (2008). Prävalenz der Hyperhomocysteinämie bei der Thrombangiitis obliterans: Spielt Homocystein pathogenetisch eine Rolle?. DMW - Deutsche Medizinische Wochenschrift. 121(46). 1417–1423. 14 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandra Dai Breakdown of academic impact, for papers by Luciano Levato Breakdown of academic impact, for papers by Andrzej Pluta Breakdown of academic impact, for papers by Elizabeth Bilotti Breakdown of academic impact, for papers by M Levade Breakdown of academic impact, for papers by Amalia Vassou Breakdown of academic impact, for papers by Roberto Freilone Breakdown of academic impact, for papers by Carla Pieresca Breakdown of academic impact, for papers by Sotirios Sachanas Breakdown of academic impact, for papers by Daniele Bertoloni
Rankless by CCL
2026